Cycle Pharmaceuticals Partners With Forma Life Sciences for CAVHANZA Supply
IRVINE, Calif., August 12, 2026 Cycle Pharmaceuticals announced a commercial manufacturing agreement with Forma Life Sciences to establish a...
chronic myeloid leukemia
Advertisement
Enliven Therapeutics Reports Positive ELVN-001 Phase 1 Data
BURLINGAME, Calif., June 11, 2026 Enliven Therapeutics announced updated positive Phase 1 clinical data for ELVN-001, its investigational BCR::ABL1-targeted...
Cycle Pharmaceuticals and Flex Pharma Advance CML Treatment with CAVHANZA Approval
CAMBRIDGE, UK, June 2, 2026 Cycle Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved CAVHANZA™...
Ascentage Pharma Highlights Hematology Pipeline at EHA
ROCKVILLE, Md. and SUZHOU, China, May 12, 2026 Ascentage Pharma announced that 17 major clinical advances across its hematology...
Enliven Therapeutics Reports Strong ELVN-001 CML Data
BOULDER, Colo., May 12, 2026 Enliven Therapeutics announced new positive clinical findings from its ongoing Phase 1 ENABLE trial...
Advertisements
Merck to Acquire Terns to Strengthen CML Pipeline
RAHWAY, New Jersey & FOSTER CITY, California, March 25, 2026 Merck & Co. has announced a definitive agreement to...
Hemostemix Advances ACP-01 With FDA Pre-IND Milestone
CALGARY, Alberta, Dec. 10, 2025 — Hemostemix Inc., a leader in autologous stem cell therapeutics, announced two pivotal corporate...
Scemblix® Gets Priority Access Under Ontario’s FAST Program
MONTREAL, QC, Dec. 10, 2025 — Scemblix® (asciminib) has become one of the first therapies prioritized for public reimbursement...
Advertisement
